Abstract
Background Estimating survival can aid care planning, but the use of absolute survival projections can be challenging for patients and clinicians to contextualize. We aimed to define how heart failure and its major comorbidities contribute to loss of actuarially predicted life expectancy.
Methods We conducted an observational cohort study of 1794 adults with stable chronic heart failure and reduced left ventricular ejection fraction, recruited from cardiology outpatient departments of 4 United Kingdom (UK) hospitals. Data from an 11-year maximum (5-year median) follow-up period (999 deaths) was used to define how heart failure and its major comorbidities impact upon survival, relative to an age-sex matched control UK population, using a relative survival framework.
Results After 10 years, mortality in the reference control population was 29%. In people with heart failure, this increased by an additional 37% (95% confidence interval 34-40%), equating to an additional 2.2-years of lost life, or a 2.4-fold (2.2-2.5) excess loss of life. This excess was greater in men than women (2.4 years [2.2-2.7] versus 1.6 years [1.2-2.0]; p<0.001). In patients without major comorbidity, men still experienced excess loss of life, whilst women experienced less and were non-significantly different from the reference population (1 year [0.6-1.5] versus 0.4 years [-0.3-1]; p<0.001). Accrual of comorbidity was associated with substantial increases in excess loss of life, particularly for chronic kidney and lung disease.
Conclusions Comorbidity accounts for the majority of lost life expectancy in people with heart failure. Women, but not men, without comorbidity experience survival close to reference controls.
Competing Interest Statement
JG has received a research grant from Medtronic. KKW has received speaker fees from Medtronic, Livanova, St. Jude Medical, Pfizer, Bayer and BMS. MTK has received speaker fees from Merck, NovoNordisk and unrestricted research awards from Medtronic. ADS has received speaker fees from Abbott, BMS, AstraZeneca, Bayer, Novartis, Boehringer Ingelheim and Servier. VKG has received speaker fees from Abbott and Novartis. All other authors have no disclosures.
Funding Statement
British Heart Foundation (PG/08/020/24617). MD and TS hold British Heart Foundation Clinical Research Training Fellowships. MP and JG hold National Institute of Health Research Fellowships. KKW holds a National Institute of Health Research Clinician Scientist Fellowship. MTK is a British Heart Foundation Professor and RMC was a British Heart Foundation Intermediate Clinical Fellow.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Leeds West Research Ethics Committee provided ethical approval (07/Q1205/17), and all patients provided written informed consent to participate
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* denotes joint first authorship
Data Availability
The datasets generated and/or analysed during the current study are not publicly available due to inclusion of potentially identifying postal codes, but are available from the corresponding author on reasonable request
Abbreviations
- ACEi
- Angiotensin converting enzyme inhibitors
- ARB
- Angiotensin receptor blockers
- β-blockers
- β-adrenoceptor antagonists
- CHF
- Chronic heart failure
- CRT
- Cardiac resynchronisation therapy
- ICD
- Implantable cardioverter-defibrillator
- CKD
- Chronic kidney disease
- COPD
- Chronic obstructive pulmonary disease
- eGFR
- Estimated glomerular filtration rate
- EHRs
- Excess hazard ratios
- LVEF
- Left ventricular ejection fraction
- MAGGIC
- Meta-analysis Global Group in Chronic Heart Failure
- NYHA
- New York Heart Association
- SHFM
- Seattle Heart Failure Model
- UK
- United Kingdom
- UK-NLT
- United Kingdom National Life Tables
